Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Public ClinicalTrials.gov record NCT02222948. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objectives: * To assess the efficacy of vatelizumab compared to placebo as measured by a reduction in new contrast-enhancing lesions (CELs) in relapsing remitting multiple sclerosis (RRMS) patients. * To evaluate multiple doses of vatelizumab for a dose-response. Secondary Objectives: * To evaluate the safety and tolerability of vatelizumab compared to placebo. * To evaluate the pharmacokinetics (PK) of vatelizumab.
Study identification
- NCT ID
- NCT02222948
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2014 (Type not available)
- Primary completion
- Apr 2016 (Actual)
- Completion
- Jul 2016 (Actual)
- Last update posted
- Dec 21, 2016
2014 – 2016
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840004 | Cullman | Alabama | 35058 | — |
| Investigational Site Number 840009 | Phoenix | Arizona | 85060 | — |
| Investigational Site Number 840005 | Fort Collins | Colorado | 80528 | — |
| Investigational Site Number 840014 | Washington D.C. | District of Columbia | 20037 | — |
| Investigational Site Number 840007 | Ormond Beach | Florida | 32174 | — |
| Investigational Site Number 840012 | Tampa | Florida | 33612 | — |
| Investigational Site Number 840001 | Latham | New York | 12210 | — |
| Investigational Site Number 840015 | Knoxville | Tennessee | 37922 | — |
| Investigational Site Number 840003 | Round Rock | Texas | 78681 | — |
| Investigational Site Number 840016 | San Antonio | Texas | 78258 | — |
| Investigational Site Number 840002 | Salt Lake City | Utah | 84103 | — |
| Investigational Site Number 840008 | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02222948, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2016 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02222948 live on ClinicalTrials.gov.